Skip to main content

QSAR, Docking, and CoMFA Studies of GSK3 Inhibitors

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

GSK-3 inhibitors are interesting candidates to develop anti-Alzheimer compounds. GSK-3β are also interesting as antiparasitic compounds active against Plasmodium falciparum, Trypanosoma brucei, and Leishmania donovani; the causative agents for Malaria, African Trypanosomiasis and Leishmaniosis. The high number of possible candidates creates the necessity of Quantitative Structure-Activity Relationship models in order to guide the GSK3 (Glycogen Synthase Kinase 3 inhibitor) synthesis. In this work, we revised different computational studies for a very large and heterogeneous series of GSK-3Is. First, we revised QSAR studies with conceptual parameters such as flexibility of rotation, probability of availability, etc. We then used the method of regression analysis and QSAR studies in order to understand the essential structural requirement for binding with receptor. Next, we reviewed 3D-QSAR, CoMFA and CoMSIA with different compounds to find out the structural requirements for GSK-3 inhibitory activity.

Keywords: Alzheimer; Bisarylmaleimides; CDK-2; CDK-4; Docking; GSK-3; Image-Based Approach; Indirubin Analogues; Indirubin Derivatives; Multi-Target QSAR; Neurofibrillary tangles (NFTs); QSAR; QSAR Modeling; SAR; Thiadiazolidinone Derivatives; anti-Alzheimer compounds; fungi; parasitic

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/138161210792389225

Affiliations: Department of Organic Chemistry, University of Vigo, Spain.

Publication date: August 1, 2010

More about this publication?
  • Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

    Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
ben/cpd/2010/00000016/00000024/art00006
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more